1-Methyl-2-butylthio-imidazol | 63348-51-6

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 1-Methyl-2-butylthio-imidazol
• 英文别名: 1-Methyl-2-n-butylthio-imidazol；2-n-Butylthio-1-methylimidazol；2-butylsulfanyl-1-methylimidazole；2-butylsulfanyl-1-methyl-1H-imidazole
• CAS: 63348-51-6
• 化学式: C₈H₁₄N₂S
• mdl: MFCD22987772
• 分子量: 170.279
• InChiKey: AKYIZTHZDJIFFG-UHFFFAOYSA-N

物化性质

• 沸点：
  80 °C(Press: 1.5 Torr)
• 密度：
  1.05±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.625
• 拓扑面积：
  43.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-Methyl-2-butylthio-imidazol 、 碘甲烷 以90%的产率得到
  参考文献：
  名称：

  KISTER J.; ASSEF G.; MILLE G.; METZGER J., CAN. J. CHEM., 1979, 57, NO 7, 813-821

  摘要：

  DOI：
• 作为产物：
  描述：

  N-甲基咪唑 、 丁硫醇 在 copper diacetate 、 silver trifluoroacetate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 12.0h， 以76%的产率得到1-Methyl-2-butylthio-imidazol
  参考文献：
  名称：

  无碱条件下路易斯酸催化的铜（II）介导的杂芳基硫醚的合成

  摘要：

  在无碱条件下，路易斯酸（Ag I，Ni II或Fe II）催化的杂芳烃和硫醇之间的Cu II介导的硫醇化反应得到了良好的收率。DMSO可作为合成杂环甲基硫醚的有效的甲基硫醇化试剂。

  DOI：

  10.1021/jo202624s

文献信息

• N,N-SUBSTITUTED 3-AMINOPYRROLIDINE COMPOUNDS USEFUL AS MONOAMINES REUPTAKE INHIBITORS
  申请人：Kurimura Muneaki

  公开号：US20090088406A1

  公开（公告）日：2009-04-02

  The present invention provides a pyrrolidine compound of General Formula (1) or a salt thereof, wherein R 101 and R 102 are each independently a phenyl group or a pyridyl group, the phenyl group or the pyridyl group may have one or more substituents selected from halogen atoms and lower alkyl groups optionally substituted with one or more halogen atoms, etc. The pyrrolidine compound or a salt thereof of the present invention is usable to produce a pharmaceutical preparation having a wider therapeutic spectrum and being capable of exhibiting sufficient therapeutic effects after short-term administration.

  本发明提供了一种吡咯烷化合物，其一般式为（1），或其盐，其中R101和R102分别是苯基或吡啶基，苯基或吡啶基可以具有一个或多个卤原子和低碳基团，可选地取代一个或多个卤原子等。本发明的吡咯烷化合物或其盐可用于制备具有更广泛治疗谱并能够在短期内展现足够治疗效果的药物制剂。
• ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS
  申请人：SCHAEFER Matthias

  公开号：US20110152290A1

  公开（公告）日：2011-06-23

  The present invention relates to compounds of the formula I, wherein A, Y, Z, R 3 to R 6 , R 20 to R 22 and R 50 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they are inhibitors of the endothelial differentiation gene receptor 2 (Edg-2, EDG2), which is activated by lysophosphatidic acid (LPA) and is also termed as LPA 1 receptor, and are useful for the treatment of diseases such as atherosclerosis, myocardial infarction and heart failure, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.

  本发明涉及式I的化合物，其中A、Y、Z、R3至R6、R20至R22和R50具有所述权利要求中指示的含义，这些化合物是有价值的药物活性化合物。具体来说，它们是内皮分化基因受体2（Edg-2，EDG2）的抑制剂，该受体被溶血磷脂酸（LPA）激活，也称为LPA1受体，可用于治疗动脉粥样硬化、心肌梗塞和心力衰竭等疾病。本发明还涉及制备式I化合物的方法、它们的用途以及包含它们的药物组合物。
• N-N-SUBSTITUTED 3-AMINOPYRROLIDINE COMPOUNDS USEFUL AS MONOAMINES REUPTAKE INHIBITORS
  申请人：KURIMURA Muneaki

  公开号：US20120065162A1

  公开（公告）日：2012-03-15

  The present invention provides a pyrrolidine compound of General Formula (1) or a salt thereof, wherein R 101 and R 102 are each independently a phenyl group or a pyridyl group, the phenyl group or the pyridyl group may have one or more substituents selected from halogen atoms and lower alkyl groups optionally substituted with one or more halogen atoms, etc. The pyrrolidine compound or a salt thereof of the present invention is usable to produce a pharmaceutical preparation having a wider therapeutic spectrum and being capable of exhibiting sufficient therapeutic effects after short-term administration.

  本发明提供了一种吡咯烷化合物通式（1）或其盐，其中R101和R102各自独立地为苯基或吡啶基，所述苯基或吡啶基可以具有一个或多个卤素原子和低碳基团中的一个或多个卤素原子等取代基。本发明的吡咯烷化合物或其盐可用于制备具有更广泛治疗谱并能够在短期内展现足够治疗效果的药物制剂。
• N,N-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors
  申请人：Otsuka Pharmaceutical Co., Ltd.

  公开号：EP2407451A1

  公开（公告）日：2012-01-18

  The present invention provides a pyrrolidine compound of General Formula (1) or a salt thereof, wherein R101 and R102 are each independently a phenyl group, which may have one or more substituents selected from halogen atoms and lower alkyl groups optionally substituted with one or more halogen atoms, etc. The pyrrolidine compound or a salt thereof of the present invention is usable to produce a pharmaceutical preparation having a wider therapeutic spectrum and being capable of exhibiting sufficient therapeutic effects after short-term administration.

  本发明提供了通式（1）的吡咯烷化合物或其盐，其中 R101 和 R102 各自独立地为苯基，该苯基可具有一个或多个选自卤素原子和任选被一个或多个卤素原子取代的低级烷基等的取代基。本发明的吡咯烷化合物或其盐可用于生产具有更广治疗范围的药物制剂，并能在短期给药后显示出足够的治疗效果。
• US7189741B2
  申请人：——

  公开号：US7189741B2

  公开（公告）日：2007-03-13